Navigation Links
NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
Date:7/22/2009

erly volunteers who are given the seasonal flu vaccine along with a 15 microgram dose of 2009 H1N1 vaccine. The H1N1 vaccine would be given to different sets of volunteers either before, after, or at the same time as the seasonal flu vaccine. If early information from those studies indicates that these vaccines are safe, similar trials in healthy children (aged 6 months to 17 years old) will start.

A panel of outside experts will conduct a close review of the safety data from these trials to spot any safety concerns in real time. Information from these studies in healthy people will help public health officials develop recommendations for immunization schedules, including the optimal dosage and number of doses for multiple age groups, including adults, the elderly, and children. Data may also be used to support decisions about the best recommendations for people in high risk groups, including pregnant women and people whose immune systems are weakened or otherwise compromised.

The trials are being conducted in a compressed timeframe in a race against the possible autumn resurgence of 2009 H1N1 flu infections that may occur at the same time as seasonal influenza virus strains begin to circulate widely in the Northern Hemisphere.

Close collaboration among NIAID, the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (a component of the Department of Health and Human Services) was key to launching the trials quickly while ensuring high standards. Following initial discussions between the agencies on trial design, NIAID prepared the protocols and submitted them to the FDA for review. FDA rapidly completed the necessary reviews and approved the trial protocols.

Since 1962, NIAID's Vaccine and Treatment Evaluation Units (VTEUs) have been intensively involved in the successful development and clinical testing of vaccines and treatments against many pathogens that threaten the health
'/>"/>

Contact: Anne A. Oplinger
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
2. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
3. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
4. NIAID honors AIDS activist Martin Delaney
5. NIAID media availability: Seizures following parasitic infection associated with brain swelling
6. NIAID awards contracts to search for protein markers of disease
7. NIAID creates HIV vaccine discovery branch
8. NIAID to advance B-cell approach to HIV vaccines
9. NIAID describes research priorities to fight drug-resistant tuberculosis
10. NIAID to convene HIV Vaccine Summit
11. NIAID scientists identify new cellular receptor for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 In ... that the pharmaceutical giant, Johnson & Johnson, is withdrawing ... it can spread undetected cancer. This important story ... (7/30), USA Today (7/31), the AP (7/30), the Pittsburgh ... morcellator tool is used during uterine procedures to, “slice ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... July 31, 2014 The Never Give Up ... supporters from11:00am-11:00pm on August 7th. Simply bring your ticket ... great food and beverages with friends and family. ... His amazing passion and contagious optimism continues to impact ... positive attitude in effort to pursue a happy life was ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and ... Magnetic bead based), Consumables & Instruments, by Application ... End users - Global Forecasts to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... along with the estimates and forecasts of the ...
(Date:7/31/2014)... 2014 Ticket Down is a reputable ... in Santa Clara, California. Fans in the United States of ... the best club and national teams in the world. Coming off ... has become the best time to be a fan of soccer ... being held on American soil this year, as well as international ...
Breaking Medicine News(10 mins):Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3
... , MORRISTOWN, N.J., Aug. 28 Watson Pharmaceuticals, ... company, today announced that its subsidiary, Watson Laboratories, Inc., has ... Administration (FDA) on its Abbreviated New Drug Application (ANDA) for ... 17 and above, as well as for prescription use in ...
... risk, researchers say , FRIDAY, Aug. 28 (HealthDay News) ... flu puts 1.5 other people at risk over the three ... the conclusion of a new study published in the journal ... showing early symptoms of the flu needs to contact their ...
... , , DETROIT, ... The Parade Company will launch The Biggest Loser: Detroit Edition contest ... selected from approximately 200 applicants to compete in this 12-week weight ... "The Biggest Loser is one of the most popular programs, ...
... 28 Children,s Hospital of Pittsburgh of UPMC has been ... leader in its use of healthcare information technology among pediatric ... KLAS interviewed leaders at virtually every hospital in the United ... software to order and chart under an organized program sponsored ...
... FRIDAY, Aug. 28 (HealthDay News) -- Men, want to keep high ... the message from a Harvard study that found that whole grain ... health. Although this study is among men, data from the Women,s ... grains as a part of a prudent, balanced diet may help ...
... TSX: COM , , VANCOUVER, ... / TSX: COM) today announced that Dr. Christian Torp-Pedersen ... 2b clinical trial of vernakalant (oral) at the European ... Barcelona, Spain from August 29 to September 2, 2009. ...
Cached Medicine News:Health News:Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use 2Health News:Study Details Swine Flu Transmission Rates 2Health News:Study Details Swine Flu Transmission Rates 3Health News:WDIV-TV, Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser: Detroit Edition 2Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 2Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 3Health News:Whole Grains, Bran May Fight Hypertension in Men 2Health News:Whole Grains, Bran May Fight Hypertension in Men 3Health News:Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009 2Health News:Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009 3
(Date:7/31/2014)... 31, 2014 Lazarus Effect, a medical device ... to facilitate removal of blood clots, announced the closing ... will support EU commercialization of several approved Lazarus Effect ... ReCover™ and Lazarus Cover™ in the United ... confidence in the value of our novel, platform technology ...
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: